Oncothyreon announces presentations at upcoming investor conferences

SEATTLE, March 8 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that management will participate in two upcoming investor conferences.

Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 22nd Annual ROTH OC Growth Stock Conference in Dana Point, CA, at 4:30 p.m. Pacific Time on Monday, March 15, 2010. A live and archived webcast of Dr. Kirkman's presentation will be accessible by visiting the Onocothyreon website www.oncothyreon.com under the "News & Events" section.

Gary Christianson, Chief Operating Officer, will present at the Life Science Innovation Northwest Conference in Seattle, WA, at 10:20 a.m. Pacific Time on Tuesday, March 16, 2010.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. The Company's oncology pipeline includes Stimuvax, a therapeutic cancer vaccine being developed by Merck KGaA, currently in Phase 3 trials for non small cell lung cancer and breast cancer and PX-866, a PI3 Kinase inhibitor expected to enter Phase 2 in mid-2010. For more information, visit www.oncothyreon.com.

SOURCE Oncothyreon Inc.